At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Aug 13, 2026 at 16:15 ET
Two insiders at Rocket Pharmaceuticals, including the COO, sold a combined $145K in open-market sales on August 11, 2026, just three days after the company reported a Q2 2026 GAAP net income of $123.2M driven by a $178.2M PRV sale. The sales are small relative to the $374M market cap (0.04%), and the cluster is not amplified per academic literature since insider sales are weak predictors. The trades likely reflect routine portfolio diversification following the positive earnings catalyst, not a bearish signal on fundamentals.
- COO Christopher Stevens sold 36,658 shares for $128K at $3.50/share on Aug 11, 2026
- Sarbani Chaudhuri sold 4,701 shares for $16K at $3.50/share on Aug 11, 2026
- Total insider sales of $145K represent 0.04% of RCKT's $374M market cap
- Sales occurred 3 days after Q2 2026 earnings release showing $123.2M net income and $283.7M cash runway into Q2 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access